LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development
8.7.2026 15:00:00 EEST | Business Wire | Press release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/
LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development
IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits.
The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leading system.
The system will be used in joint R&D efforts towards fault-tolerant quantum computing and advancements in hybrid computing. This will support new inventions on the critical path to fault-tolerant quantum computing and to enable new commercialization opportunities.
This forward-looking development path ensures that European users can experiment today while preparing for fully scalable quantum platforms tomorrow. The system will also provide European end-users with the high-performance quantum computing resources needed for research and innovation, and for building national know-how and expertise.
"CSC and the LUMI AI Factory are exactly the kind of partners that define what production quantum computing looks like in practice — world-class HPC infrastructure, a deep commitment to research excellence, and the ambition to lead rather than follow," said Jan Goetz, CEO and Co-founder, IQM Quantum Computers. "Delivering IQM Halocene to CSC means Europe's most powerful quantum computer will sit at the heart of one of the world's leading research computing environments. This is a milestone for IQM, CSC, for Finland, and for the European quantum ecosystem."
The system, named LUMI-IQ, will be integrated into the LUMI AI Factory at CSC – IT Center for Science, Finland's national center of expertise in information technology and home to the LUMI supercomputer, one of the world's most powerful supercomputers.
This integration of quantum technologies with AI and high-performance computing opens the door to breakthroughs that classical computing alone cannot achieve. LUMI-IQ will comprise both hardware and software solutions, offering capabilities for research, development, and education.
"As part of the LUMI AI Factory, LUMI-IQ will bring together world-leading AI, data, high-performance computing and quantum acceleration in one powerful hybrid environment. By connecting quantum concepts and algorithms with intelligent software tools and real-world applications, it will open new possibilities for scientific discovery and RDI, from materials and health to energy and fundamental science. At the same time, it will help Europe build the knowledge, skills, and capabilities needed for the next era of innovation, including the path toward fault-tolerant quantum computing," said Kimmo Koski, Managing Director of CSC – IT Center for Science.
"Already the first system delivered in 2027 will come with a state-of-the-art quantum processing unit (QPU) with 150 qubits. This is only the beginning, however. Over the next years, LUMI-IQ will evolve into a fault-tolerant quantum computer through a series of upgrades that increase both qubit count and performance, making the LUMI AI Factory a world-leading European hybrid platform combining AI and quantum computing," describes Mikael Johansson, Manager for Quantum Technologies at CSC – IT Center for Science.
The LUMI-IQ quantum computer will be jointly funded by the EuroHPC Joint Undertaking, Finland, Czechia, Norway and Poland.
As disclosed in IQM's prospectus on 1 July 2026, the total value of the contract is approximately equal to IQM's total revenue for the financial year ended 31 December 2025.
This announcement follows IQM's landmark dual listing on Nasdaq in the United States and the Helsinki Stock Exchange in Finland, making it the first European quantum computing company to be publicly traded.
IQM has sold 23 quantum systems globally — more than any other quantum hardware manufacturer — with its systems integrated into four of the leading supercomputing centers in the world.
About CSC – IT Center for Science
CSC is a Finnish center of expertise in ICT that provides world-class services for research, education, culture, public administration and enterprises, to help them thrive and benefit society at large. www.csc.fi
About IQM Quantum Computers
IQM Quantum Computers (Nasdaq: IQMX) is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to enterprises, research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM's on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018 and headquartered in Finland, with major operations in Munich, IQM employs over 400 people and operates across Europe, Asia, and North America. IQM is the first publicly listed European quantum company on Nasdaq Stock Market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260708006791/en/
Contacts
IQM Media contact:
Email: press@iqm.tech
M: +49 151 1843 4887
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 15:30:00 EEST | Press release
Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and smaller, regional community-based networks alike. The financing will scale manufacturing and accelerate commercial deployment, and continue clinical and product development across Leo Cancer Care’s integrated u
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 15:00:00 EEST | Press release
Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell, Director at SLR Consulting and Executive Sponsor of DIMPACT. “Accurately calculating digital emissions requires a de
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 15:00:00 EEST | Press release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates th
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 15:00:00 EEST | Press release
STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en/ Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom